Rapid communication · 29 May 2025
Mini reviewPublished 4 Dec 2019
Imeglimin: Therapeutic Option for Achieving Glycemic Control
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Imeglimin is a new class of drug which has introduced recently. The molecular mechanisms are unknown, although imeglimin improves insulin sensitivity in humans. Pre-clinical studies had confirmed that imeglimin favouring lipid oxidation in liver and preserving mitochondrial function from oxidative stress, therefore normalizes glucose tolerance and insulin sensitivity. The main objective of this review article is to highlight updates of new class of drug which is imeglimin and generated a huge interest after recently conducted EASD at Barcelona.
Keywords
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Diabetes & Metabolism.
Rapid communication · 29 May 2025
Genetic and epigenetic markers for gdm risk
Short communication · 29 May 2025
Metabolic syndrome: Diet, timed eating, supplements
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Diabetes & Metabolism
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Dr. Subhash Kumar”